Skip to main content
. 2022 May 16;13(8):2656–2661. doi: 10.7150/jca.71494

Figure 1.

Figure 1

Droplet digital PCR assays using circulating tumor DNA extracted from plasma of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab. (A) Representative droplet digital PCR assay for detecting CTNNB1 mutation at Thr41 (A121G). Black, green, blue, and orange dots indicate empty droplets, wild-type DNA HEX-positive droplets, mutant DNA FAM-positive droplets, and wild-type and mutant double-positive droplets, respectively. (B) Summary of results for the detection of CTNNB1 mutations in all patients. (C) Progression-free survival of patients based on CTNNB1 mutations.